Floatz logo

Eloxatin

CYP3A Inhibitor

German Cancer Research CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the CYP3A Inhibitor cohort.

Asset / SponsorPhaseRating
Glofitamab
German Cancer Research Center
Phase 1CC
Cobicistat
German Cancer Research Center
Phase 1CC
Obinutuzumab
German Cancer Research Center
Phase 1CC

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →